ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid

Amgen is developing two bispecific T-cell engagers (BiTEs) for multiple myeloma, one of which is designed with a longer half-life that could lessen the infusion time required for patients. Dana-Farber researchers presented promising preclinical data on the follow-up BiTE, AMG 701, at the ASH annual meeting. But rivals loom.